Novo Nordisk have announced the launch of Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of type II diabetes now available in the U.K.
Ozempic primarily works by mimicing the function of the GLP-1 hormone produced in the gut that lowers blood sugar levels and also ameliorates glucose absorption into the bloodstream.
Doctors have stated that the new medication should be use alongside a balanced diet and regular excercise and as mono therapy when metformin is not appropriate or not well tolerated.
Novo Nordisk currently enjoys a strong presence in the diabetes market with an estimated global value market share of around 28% in addition to its insulin market which stands strong on a 45% market share.
Specialist doctors have consistently warned patients that uncontrolled diabetes can lead to a vast array of other illnesses including cardiovascular disease which affects nearly twice as many individuals with type II diabetes.
The official EU licensing is based on results from its SUSTAIN trial which demonstrated superior glycemic control as well as superior and sustained weightless compared to dulaglutide.